banner

MIURA

  • email
  • twitter
  • linkedin
  • facebook

Miura America is a leading provider of high-efficiency, modular steam boiler systems engineered to help facilities improve reliability, reduce operating costs, and simplify steam production. Manufactured in Rockmart, Georgia, Miura boilers are designed for fast startup, compact footprints, responsive load following, and efficient multi-boiler operation. Miura supports customers across food and beverage, healthcare, pharmaceutical, laundry, manufacturing, and other steam-intensive industries with a complete portfolio that includes boilers, water treatment, monitoring and controls, maintenance programs, and lifecycle support. Its modular approach allows facilities to match steam production to demand while supporting system resiliency through multiple units working together. Backed by a nationwide network of representatives and service professionals, Miura helps customers design, operate, and maintain steam systems for long-term performance. From new installations to plant upgrades, Miura provides integrated solutions focused on efficiency, reliability, ease of operation, and dependable support throughout the equipment lifecycle for facilities of virtually any size nationwide.

Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma
Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF...

Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones
CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of...

Novartis to Present Pivotal Data in Hematologic and Solid Tumor Cancers at 2016 ASCO Annual Meeting
Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical...

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar +...

Positive CHMP Opinion for Novartis Metastatic Melanoma Treatment Announced Today.
Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones CHMP positive opinion for EU approval of...

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a...

Novartis Drug PKC412 (Midostaurin) Receives Breakthrough Therapy Designation From the FDA for Newly-Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation...

Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in...

MONALEESA-2 Trial of Novartis' LEE011 (Ribociclib) Stopped Due to Positive Efficacy Results at Interim Analysis in HR+/HER2- Advanced Breast Cancer
Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending...

Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma
Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib...

https://media.caboodleai.net/abma/companies/m-2ad94b1f-3c2a-4bcf-8ef5-c3245ad5eb4a.jpg

geo-icon
2200 Steve B Smith Blvd
Rockmart, GA, 30153
USA
Kyle Richards
6786850929
kyle.richards@miuraz.com